CompletedNCT00698022
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
Medication studyAges 18–40IndiaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 40 years.
- Listed locations
- MumbaiSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateNovember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 76
- Sponsor
- Corcept Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- India
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT00698022
- Official title
Show the full official title
A 4-week, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
Get this study by email
Recruitment & locations
CompletedMumbai
Questions about this study
Who is behind this study?
The study sponsor is Corcept Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Risperidone, Mifepristone, Risperidone-matched placebo and Mifepristone-matched placebo.
Who was this study for?
Listed age limits: 18 years to 40 years.
